Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 3
2011 3
2012 3
2013 3
2014 5
2015 2
2016 3
2017 2
2018 4
2019 3
2020 4
2021 3
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Management of hepatic complications in HIV-infected persons.
Sulkowski MS. Sulkowski MS. J Infect Dis. 2008 May 15;197 Suppl 3:S279-93. doi: 10.1086/533414. J Infect Dis. 2008. PMID: 18447614 Review.
Liver disease-related deaths mostly result from chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). ...Management of these conditions in HIV-infected persons requires careful consideration, balancing the potential benefits of therapy with the pot …
Liver disease-related deaths mostly result from chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). ...Man …
Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
Tsai MC, Chang KC, Yen YH, Wu CK, Lin MT, Hu TH. Tsai MC, et al. Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):208-213. doi: 10.1097/MEG.0000000000001711. Eur J Gastroenterol Hepatol. 2021. PMID: 32371826
BACKGROUND AND AIM: Tenofovir disoproxil fumarate (TDF) and entecavir are effective antiviral medications that are recommended as first-line monotherapies for the treatment of chronic hepatitis B (CHB) infection, including decompensated liver cirrhosis with ascites. …
BACKGROUND AND AIM: Tenofovir disoproxil fumarate (TDF) and entecavir are effective antiviral medications that are recommended as fir …
Perfused human hepatocyte microtissues identify reactive metabolite-forming and mitochondria-perturbing hepatotoxins.
Rowe C, Shaeri M, Large E, Cornforth T, Robinson A, Kostrzewski T, Sison-Young R, Goldring C, Park K, Hughes D. Rowe C, et al. Toxicol In Vitro. 2018 Feb;46:29-38. doi: 10.1016/j.tiv.2017.09.012. Epub 2017 Sep 15. Toxicol In Vitro. 2018. PMID: 28919358
Hepatotoxins cause liver damage via many mechanisms but the formation of reactive metabolites and/or damage to liver mitochondria are commonly implicated. ...These data highlight the potential utility of perfused metabolically functional human liver microtiss …
Hepatotoxins cause liver damage via many mechanisms but the formation of reactive metabolites and/or damage to liver mitochond …
Liver-Targeted Co-delivery of Entecavir and Glycyrrhetinic Acid Based on Albumin Nanoparticle To Enhance the Accumulation of Entecavir.
He S, Lin Q, Qu M, Wang L, Deng L, Xiao L, Zhang Z, Zhang L. He S, et al. Mol Pharm. 2018 Sep 4;15(9):3953-3961. doi: 10.1021/acs.molpharmaceut.8b00408. Epub 2018 Aug 23. Mol Pharm. 2018. PMID: 30110554
Although the treatment for hepatitis B has been improved over the years, many therapeutic drugs still have either severe adverse effects or insufficient effectiveness via systemic administration. In this study, we confirmed that glycyrrhetinic acid can enhance the a …
Although the treatment for hepatitis B has been improved over the years, many therapeutic drugs still have either severe adverse e …
Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.
Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Rojas-Feria M, et al. World J Gastroenterol. 2013 Nov 14;19(42):7327-40. doi: 10.3748/wjg.v19.i42.7327. World J Gastroenterol. 2013. PMID: 24259964 Free PMC article. Review.
Most of the drugs used for IBD treatment may induce hepatotoxicity, although the incidence of serious adverse events is low. Abnormalities in liver biochemical tests associated with aminosalicylates are uncommon and are usually not clinically relevant. ...Thiopurine …
Most of the drugs used for IBD treatment may induce hepatotoxicity, although the incidence of serious adverse events is low. Abnormal …
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Ha Y, et al. Sci Rep. 2020 Aug 11;10(1):13537. doi: 10.1038/s41598-020-70433-z. Sci Rep. 2020. PMID: 32782369 Free PMC article.
Conflicting results have been reported regarding which of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) is associated with better outcomes. ...
Conflicting results have been reported regarding which of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) is associated with b …
Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Sulkowski MS, et al. J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11. J Hepatol. 2022. PMID: 35697332 Free article. Clinical Trial.
The safety of VBR+ETV was similar to PBO+ETV. All treatment-emergent adverse events and laboratory abnormalities were Grade 1/2. There were no deaths, serious adverse events, or evidence of drug-induced liver injury. ...Herein, we show th …
The safety of VBR+ETV was similar to PBO+ETV. All treatment-emergent adverse events and laboratory abnormalities were Grade 1/2. Ther …
Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.
Tang K, Cheng H, Wang H, Guo Y. Tang K, et al. Medicine (Baltimore). 2023 Feb 10;102(6):e32894. doi: 10.1097/MD.0000000000032894. Medicine (Baltimore). 2023. PMID: 36820558 Free PMC article.
BACKGROUND: Tenofovir and Entecavir are recommended as the first-line medicine of treatment for chronic hepatitis B. ...CONCLUSION: The occurrence rate of hepatocellular carcinoma after the treatment of tenofovir for chronic hepatitis B is lower than that of the treatment …
BACKGROUND: Tenofovir and Entecavir are recommended as the first-line medicine of treatment for chronic hepatitis B. ...CONCLUSION: T …
Graves' disease overlapping with chronic hepatitis B and methimazole-induced liver injury and autoimmune hepatitis: a case report.
Zheng M, Cui S, Zhang W, Brigstock DR, Gao R. Zheng M, et al. BMC Gastroenterol. 2022 Feb 10;22(1):59. doi: 10.1186/s12876-022-02133-z. BMC Gastroenterol. 2022. PMID: 35144533 Free PMC article.
BACKGROUND: Liver injury related to Graves' Disease (GD) includes hepatotoxicity of thyroid hormone excess, drug-induced liver injury, and changes resulting from concomitant liver disease. ...The patient was diagnosed with GD overl …
BACKGROUND: Liver injury related to Graves' Disease (GD) includes hepatotoxicity of thyroid hormone excess, drug-ind …
Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.
Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, Jiao J, Wang JB. Xu Y, et al. World J Gastroenterol. 2015 Jul 7;21(25):7869-76. doi: 10.3748/wjg.v21.i25.7869. World J Gastroenterol. 2015. PMID: 26167087 Free PMC article.
AIM: To evaluate the clinical outcomes of 240-wk treatment with entecavir (0.5 mg) in Chinese nucleoside-naive patients with cirrhosis. METHODS: A total of 204 nucleoside-naive patients with compensated (n = 96) or decompensated (n = 108) hepatitis B virus (HBV)-induced …
AIM: To evaluate the clinical outcomes of 240-wk treatment with entecavir (0.5 mg) in Chinese nucleoside-naive patients with cirrhosi …
41 results